Indo-Bangla Pharmaceuticals Limited announcements
129 Dhaka Stock Exchange announcements for Indo-Bangla Pharmaceuticals Limited (IBP) since 2018: results, dividends, board meetings, AGMs, record dates and other price-sensitive information. Showing 2023 (20).
- Resumption after Record date
Trading of the shares of the company will resume on 20.11.2023.
- Suspension for Record date
Trading of the shares of the company will remain suspended on record date i.e., 19.11.2023.
- (Q1 Un-audited): EPS was Tk. 0.01 for July-September, 2023 as against Tk. 0.17 for July-September, 2022. NOCFPS was Tk.
(Q1 Un-audited): EPS was Tk. 0.01 for July-September, 2023 as against Tk. 0.17 for July-September, 2022. NOCFPS was Tk. 0.09 for July-September, 2023 as against Tk. 0.02 for July-September, 2022. NAV per share was Tk. 13.97 as on September 30, 2023 and Tk. 13.96 as on June 30, 2023. (cont.)
- Q1 Financials
(Continuation news of IBP): Reasons for deviation: EPS has been decreased as compared to the same period of the previous year due to decrease in sales revenue and also increase in production cost for increase in all raw material prices and significant volatility of the foreign currency market. NOCFPS has been increased during the period due to increased collection from customers than payment to Suppliers. (end)
The first part of this announcement is missing from the archive. - Spot News
Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled as per spot settlement cycle from 15.11.2023 to 16.11.2023 and trading of the shares will remain suspended on record date i.e., 19.11.2023.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 14, 2023 at 4:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended September 30, 2023.
- The Board of Directors has recommended No Dividend for the year ended June 30, 2023. Date of AGM: 28.12.2023, Time: 11:0
The Board of Directors has recommended No Dividend for the year ended June 30, 2023. Date of AGM: 28.12.2023, Time: 11:00 AM, Venue: Digital Platform. Record date: 19.11.2023. The Company has also reported EPS of Tk. 0.07, NAV per share of Tk. 13.96 and NOCFPS of Tk. 0.63 for the year ended June 30, 2023 as against Tk. 0.22, Tk. 13.98 and Tk. 0.79 respectively for the year ended June 30, 2022. (cont.)
- Dividend Declaration
(Continuation news of IBP): Reasons for decrease in EPS and NOCFPS: EPS has been decreased due to increase of import costs and decline in the demand of the product. NOCFPS has been decreased due to increase in payment for cost and expenses during July 2022 to June 2023. (end)
The first part of this announcement is missing from the archive. - Price Limit Open
There will be no price limit on the trading of the shares of the Company today (29.10.2023) following its corporate declaration. However, the floor price shall be applicable accordingly.
- Board Meeting schedule under LR 19(1)
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 28, 2023 at 4:00 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2023.
- The auditor of Indo-Bangla Pharmaceuticals Limited has given the \"Qualified Opinion\" paragraphs in the Auditor\'s Repo
The auditor of Indo-Bangla Pharmaceuticals Limited has given the \"Qualified Opinion\" paragraphs in the Auditor\'s Report for the year ended on June 30, 2022. \"Basis for Qualified Opinion: 2. Total VAT payable against Sales was Tk. 3,30,18,879.00 as per VAT Return (9.1). The company paid Tk. 3,30,18,879.00 as per VAT payment chalan produced to us. We have checked the correctness of the payment of VAT through online. Total payment was Tk. 51,53,000.00 on the basis of online checking\"
- Q3 Financials
(Q3 Un-audited): EPS was Tk. 0.01 for January-March 2023 as against Tk. 0.12 for January-March 2022; EPS was Tk. 0.10 for July 2022-March 2023 as against Tk. 0.62 for July 2021-March 2022. NOCFPS was Tk. 0.06 for July 2022-March 2023 as against Tk. 0.55 for July 2021-March 2022. NAV per share was Tk. 13.99 as on March 31, 2023 and Tk. 13.98 as on June 30, 2022.
- Reschedule of Board Meeting under LR 16(1)
The Company has further informed that the meeting of the Board of Directors of the Company as per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, will be held on May 25, 2023 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2023.
- Postponement of Board Meeting schedule under LR 16(1)
The Company has further informed that due to unavoidable circumstances, the meeting scheduled to be held on April 30, 2023 at 4:00 PM as per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2023, has been postponed. New date and time of the meeting will be notified later.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 30, 2023 at 4:00 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2023.
- The auditor of the \"Indo-Bangla Pharmaceuticals Ltd.\" has given the \"Qualified Opinion\" paragraph in the Auditor\'s
The auditor of the \"Indo-Bangla Pharmaceuticals Ltd.\" has given the \"Qualified Opinion\" paragraph in the Auditor\'s Report for the year ended June 30, 2022. \"Basis for Qualified Opinion: Subject to the following observation we believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. 1. Note no. 8.01: Bank balance at First Security Islami Bank, Bashundhara Branch, Dhaka account no. 017711100000302 (cont.)
- (Continuation news of IBP): showed balance Tk. 51,56,160.00. On that basis statement of accounts have been prepared. To
(Continuation news of IBP): showed balance Tk. 51,56,160.00. On that basis statement of accounts have been prepared. To confirm the balance we have collected the balance confirmation certificate directly from the said bank branch. Branch management certified that the balance as on 30th June, 2022 was Tk. 1,56,160.00.\" (end)
The first part of this announcement is missing from the archive. - (Q2 Un-audited): EPS was Tk. (0.08) for October-December 2022 as against Tk. 0.17 for October-December 2021; EPS was Tk.
(Q2 Un-audited): EPS was Tk. (0.08) for October-December 2022 as against Tk. 0.17 for October-December 2021; EPS was Tk. 0.09 for July-December 2022 as against Tk. 0.50 for July-December 2021. NOCFPS was Tk. 0.05 for July-December 2022 as against Tk. 0.40 for July-December 2021. NAV per share was Tk. 13.98 as on December 31, 2022 and Tk. 13.98 as on June 30, 2022. Reasons for deviation in EPS, NAVPS and NOCFPS: EPS has decreased (cont.)
- Q2 Financials
(Continuation news of IBP): due to decreased sales as 9 listed products was banned temporarily for marketing and selling by order of Directorate General of Drug Administration (DGDA) and also due to increase in cost of goods sold and financial expenses. NOCFPS has decreased due to increase in cost of goods sold resulted from considerable growth in price of raw materials and increase in cash paid to suppliers, employees and others. (end)
The first part of this announcement is missing from the archive. - Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 30, 2023 at 4:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended December 31, 2022.
Source: Dhaka Stock Exchange announcements. Some posts before 2014 have no title, and 2014–2020 coverage is incomplete.